- Home
- ACTU vs OFS Comparison
ACTU vs OFS Comparison
Compare ACTU & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- OFS
- Stock Information
- Founded
- ACTU 2015
- OFS 2001
- Country
- ACTU United States
- OFS United States
- Employees
- ACTU N/A
- OFS N/A
- Industry
- ACTU
- OFS Finance/Investors Services
- Sector
- ACTU
- OFS Finance
- Exchange
- ACTU NYSE
- OFS Nasdaq
- Market Cap
- ACTU 135.0M
- OFS 110.3M
- IPO Year
- ACTU 2024
- OFS 2012
- Fundamental
- Price
- ACTU $8.00
- OFS $8.44
- Analyst Decision
- ACTU Strong Buy
- OFS
- Analyst Count
- ACTU 1
- OFS 0
- Target Price
- ACTU $20.00
- OFS N/A
- AVG Volume (30 Days)
- ACTU 42.0K
- OFS 65.6K
- Earning Date
- ACTU 05-21-2025
- OFS 05-01-2025
- Dividend Yield
- ACTU N/A
- OFS 16.09%
- EPS Growth
- ACTU N/A
- OFS N/A
- EPS
- ACTU N/A
- OFS 2.12
- Revenue
- ACTU N/A
- OFS $47,964,000.00
- Revenue This Year
- ACTU N/A
- OFS N/A
- Revenue Next Year
- ACTU N/A
- OFS N/A
- P/E Ratio
- ACTU N/A
- OFS $3.98
- Revenue Growth
- ACTU N/A
- OFS N/A
- 52 Week Low
- ACTU $5.51
- OFS $7.75
- 52 Week High
- ACTU $11.73
- OFS $10.04
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- OFS 45.38
- Support Level
- ACTU N/A
- OFS $8.15
- Resistance Level
- ACTU N/A
- OFS $8.60
- Average True Range (ATR)
- ACTU 0.00
- OFS 0.42
- MACD
- ACTU 0.00
- OFS -0.07
- Stochastic Oscillator
- ACTU 0.00
- OFS 34.15
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.